大麻素的治疗潜力,用于治疗阿托皮性皮肤炎
Adriel Aparecido Geraldo Stoco1, Priscila Gava Mazzola2
1Faculty of Pharmaceutical Sciences, Universidade Estadual de Campinas, Rua Cândido Portinari, 200, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, 13083-871, Brazil. adriel.ap18@gmail.com.
Journal of cannabis research
|August 16, 2025
概括
大麻素显示出通过减少炎症和来治疗亚托皮炎 (AD) 的前景. 需要进一步的研究来证实这些化合物的安全性和有效性,作为AD补充疗法.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 自然产品 自然产品
背景情况:
- 无氧性皮肤炎 (AD) 是一种慢性皮肤疾病,其特征是皮肤屏障受损,炎症和强烈的.
- 目前的治疗方法,如局部葡萄皮质激素,是有效的,但具有局限性和长期使用的副作用.
- 需要新的治疗策略来管理AD症状并改善患者的治疗结果.
研究的目的:
- 审查大麻素作为亚托皮性皮肤炎的补充治疗方法的治疗潜力.
- 探索各种大麻素的抗炎,抗,抗氧化和抗微生物特性.
- 确定需要进一步研究大麻素对AD的疗效和安全性.
主要方法:
- 对皮肤炎中大麻素的临床前和临床研究的文献综述.
- 对内源性,植物性 (植物性大麻素) 和合成大麻素的研究分析.
- 评估拟议的作用机制,包括抗炎和抗作用.
主要成果:
- 包括大麻 (CBD),Δ-9-四大麻 (THC) 和棕甲基乙醇胺 (PEA) 在内的大麻素显示出改善AD症状的潜力.
- 促进其治疗作用的关键特性包括抗炎,抗和抗氧化活性.
- 一些大麻素也表现出抗微生物特性,这可能有利于AD管理.
结论:
- 大麻素显示出有前途的治疗潜力,作为亚托邦性皮肤炎的补充剂.
- 它们的抗炎和抗作用对于管理AD症状尤为重要.
- 进一步高质量的临床和临床前试验对于确定大麻素在阿兹海默症治疗中的有效性和安全性至关重要.
相关概念视频
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
366
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
366
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
326
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
326
01:25Analgesia and Pain Management
791
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
791
01:20The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232